Indefinite Delivery Contract SPE2DR25D9952

The federal contract IDV award SPE2DR25D9952 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,999,999, covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

The contract is part of the DLA's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), which aims to establish multiple prime vendor contracts to provide worldwide pharmaceutical support to various DoD customers. The upcoming solicitation for PPV-G GEN V, expected to be issued in March 2024, will have a total estimated value of $30.3 billion and be awarded on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. The contract will have a 30-month base period and three 30-month option periods, and the award will be made on a Lowest Price Technically Acceptable (LPTA) basis, with the potential use of a reverse auction to determine the final distribution fees.